Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer ...

The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.

Pfizer's dividend isn't the only thing going for it. UPS is poised to turn the corner after a few bad years for its stock. If ...

It’s been a year of big stories about Big Pharmas in the healthcare marketing world. | It’s been a year of big stories about ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look ...

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is ...

What we can glean from the pattern of accidental discoveries in science, especially in the pharmaceutical industry, and their ...

We recently published a list of the 8 Best Dividend Leaders to Buy According to Wall Street Analysts. In this article, we are ...

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

Louis Llovio is the deputy managing editor at the Business Observer. Before going to work at the Observer, the longtime ...